BC-7013

BC-7013 is a novel semi-synthetic pleuromutilin derivative. BC-7013 has excellent activity against Gram-positive pathogenic bacteria. BC-7013 exhibits potent antibacterial properties against both Staphylococcus, Streptococcus and penicillin-resistant Streptococcus pneumoniae. BC-7013 has activity against Gram-positive pathogenic bacteria, BC-7013 is useful in the research of acute bacterial skin and skin structure infection (ABSSSI) [1].

Product Specifications

CAS Number

[1028291-66-8]

Product Name Alternative

KPT-8602

UNSPSC

12352005

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/bc-7013.html

Purity

99.04

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(CSC1=CC=CC(CO)=C1)O[C@H]2[C@]3(C)[C@@H](CC[C@]4([C@H]([C@@H]([C@](C=C)(C2)C)O)C)[C@@]3([H])C(CC4)=O)C

Molecular Formula

C29H40O5S

Molecular Weight

500.69

References & Citations

[1]Shang R, et al. Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives. Curr Top Med Chem. 2013;13 (24) :3013-25.|[2]Biedenbach D J, et al. In vitro antibacterial spectrum of BC-7013, a novel pleuromutilin derivative for topical use in humans. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009, 49: 199